SecBot SecBot

PCRX

Pacira BioSciences, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001396814 Biotech & Drug Discovery
$36.48 +0.02 (+0.05%)
Nov 16 4:00 PM ET · prev $36.46
Market cap
$1.5B
Small cap
Consensus
Hold
0% Buy or better · 14 analysts
Median target
$36.50
+0% · range $25.00–36.50
1 year
+52.8%
from $23.88 · Nov 17
30 days
+0.4%
from $36.34
52-week range
$19.16–36.49
−0% from high · low Jan 16
Avg volume 20D
1.07M
shares / day
Short interest
3.35M
≈8.3% of shares · −21.4%
Days to cover
3.9
at average volume
Insider net
−$1.7M
0 buyers · 5 sellers · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
25
analyzed by SecBot
SecBot read MIXED 13 reports · 90 days
Balance 2 bearish · 4 bullish · 2 mixed · 5 neutral oldest → newest, height = score
Avg score ·High conf. 13/13

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    5 insiders sold $1.7M.

  • InstitutionsBULLISH

    Q3 2026: 24 added (0 new), 13 trimmed or exited.

  • AnalystsMIXED

    0 of 14 rate it Buy or better. Median target $36.50 (+0%).

  • Short sellersCOVERING

    Short interest −21.4% to 3.35M shares. 3.9 days to cover, ≈8.3% of shares.

  • TrendUPTREND

    16% above its 50-day average. New closing high $36.49 on Nov 10.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
JPMORGAN CHASE & COADD442,012$11.3M
FMR LLCADD410,000$10.3M
VICTORY CAPITAL MANAGEMENT INCADD280,566$7.0M
PUBLIC SECTOR PENSION INVESTMENT BOARDADD189,815$6.9M
Empowered Funds, LLCADD262,102$6.6M
MARSHALL WACE, LLPADD239,881$6.0M
BNP PARIBAS FINANCIAL MARKETSDOUBLED186,586$4.7M
Universal- Beteiligungs- und Servicegesellschaft mbHADD176,189$4.4M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

14 analysts
Hold 0% rate it Buy or better
Strong Buy0Buy0Hold11Sell1Strong Sell2
12-month targets · 7 analysts

Price is inside the target range. Median implies +0%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Oct 9, 2026Truist Securities
DOWNGRADE
DOWNGRADEHold
Oct 9, 2026RBC Capital
MAINTAIN
MAINTAINSector Perform
Oct 9, 2026HC Wainwright & Co.
DOWNGRADE
DOWNGRADENeutral
Oct 8, 2026JP Morgan
UPGRADE
UPGRADENeutral
Oct 8, 2026Jefferies
DOWNGRADE
DOWNGRADEHold
Oct 8, 2026Needham
DOWNGRADE
DOWNGRADEHold

Insider ledger

Form 4
$0
bought · 0 insiders
$1.7M
sold · 5 insiders
DateInsiderTypeValue
Oct 30, 2026
Cross Shawn
Chief Financial Officer
Oct 30, 2026
TAX W/H$347.2K
Oct 8, 2026
RIKER LAUREN
Senior Vice President, Finance
Oct 8, 2026
EXERCISE$194.1K
Oct 8, 2026
RIKER LAUREN
Senior Vice President, Finance
Oct 8, 2026
SELL$217.9K
Aug 17, 2026
SLONIN JONATHAN
Chief Medical Officer
Aug 17, 2026
SELL$70.6K
Jun 11, 2026
RIKER LAUREN
Senior Vice President, Finance
Jun 11, 2026
SELL$143.7K
Jun 10, 2026
Brege Laura
Director
Jun 10, 2026
AWARD6,405 sh
Jun 10, 2026
Froimson Mark
Director
Jun 10, 2026
AWARD6,405 sh
Jun 10, 2026
CHRISTIE CHRISTOPHER
Director
Jun 10, 2026
AWARD6,405 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q$0.73$0.65–$0.89-4.9%$181.5M
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
3,348,320
shares short
-21.4%
vs prior settlement
3.9
days to cover
≈8.3%
of shares outstanding
Trading halts
Nov 16, 2026🔒 Fresh data, subscribers only
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 Trading halt
🔒 Fresh data, subscribers only
Nov 12, 2026 SEC
The Ninth Circuit reversed in part the District Court's judgment in Pacira's royalty dispute with RDF, ruling that…
8-K · Impact 6/10
Nov 12, 2026 SEC
Viatris and its wholly owned subsidiary Peach Purchaser Sub Inc. filed Amendment No. 1 to their Schedule TO, updating…
SC TO-T/A · Impact 7/10
Nov 12, 2026 SEC
Pacira BioSciences filed Amendment No. 2 to its Schedule 14D-9, updating the legal proceedings section to disclose…
SC 14D-9/A · Impact 3/10
Oct 30, 2026 Insider
Cross Shawn surrendered for taxes 9,540 shares
Chief Financial Officer @ $36.39 ($347.2K)
Oct 8, 2026 Insider
RIKER LAUREN acquired via exercise 6,000 shares
Senior Vice President, Finance @ $32.35 ($194.1K)
Oct 8, 2026 Insider
RIKER LAUREN sold 6,000 shares
Senior Vice President, Finance @ $36.32 ($217.9K)
Sep 30, 2026 Inst.
JPMORGAN CHASE & CO · ADD
442,012 shares ($11.3M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
3 drugs tracked · Drug pipeline →
Recent

SecBot reports

25 filings · 4 press releases · 5 bullish · 2 bearish · 7 mixed · 11 neutral
All PCRX filing & press-release reports (29)